Yes, it can be combined with other antihypertensives, but the combination may produce additive blood-pressure lowering effects. Your clinician should monitor your readings and adjust doses as needed.
Sit or lie down immediately, raise your legs if possible, and seek medical attention if symptoms persist or you experience fainting.
Extended-release tablets (such as Procardia) provide a gradual release of nifedipine over 24 hours, allowing once-daily dosing. Immediate-release forms release the drug quickly and often require multiple daily doses.
In the UK, Procardia 30 mg tablets are typically white with a distinctive imprint of “30” on one side, but appearance may vary by manufacturer.
Yes, you may travel with a prescription-only medication, but keep it in its original packaging with the prescription label. Carry a copy of the prescription and be prepared for security checks.
Grapefruit juice can inhibit the metabolism of nifedipine, leading to higher blood levels and an increased risk of side effects. It is advisable to limit or avoid grapefruit while taking Procardia.
Mild hepatic impairment may be tolerated, but dose adjustments are often recommended. Your doctor will assess liver function before deciding on the appropriate dose.
Therapeutic effects can be observed within a few days, but full blood-pressure control may take several weeks of consistent dosing.
Nifedipine is classified as a pregnancy-category D drug in the UK, indicating potential risk to the fetus. It should only be used if the benefit outweighs the risk and after specialist consultation.
Brand-name products generally cost more than their generic equivalents due to branding and marketing expenses. Prices vary across pharmacies and NHS prescriptions; generic nifedipine may be available at a lower cost when prescribed.
Procardia is a brand-name medication that contains nifedipine as its active ingredient. Nifedipine belongs to the calcium-channel blocker class of drugs and is used to treat conditions that affect the heart and blood pressure. In the United Kingdom, Procardia is a prescription-only product (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is supplied as a 30 mg oral pill.
Nifedipine blocks L-type calcium channels located in the smooth muscle of blood vessels and in cardiac muscle. By preventing calcium entry, the medication causes vascular smooth-muscle relaxation, leading to:
The onset of action for the extended-release 30 mg tablet is typically within a few hours, with a steady therapeutic effect that lasts 24 hours, allowing once-daily dosing for many patients.
Procardia is licensed in the UK for the following indications:
These uses are supported by MHRA-approved labeling and clinical guidelines for the management of cardiovascular disease.
Off-label use of nifedipine has been investigated for some vascular conditions, but it is not approved by the MHRA for these indications.
Raynaud’s phenomenon - Small studies have shown that nifedipine can improve blood flow in the fingers and toes of patients with severe Raynaud’s. The evidence consists mainly of open-label trials and a few randomized controlled studies. Disclaimer: Off-label use requires medical supervision and an individualized risk assessment.
Pulmonary hypertension (selected cases) - Limited data from early-phase trials suggest potential benefit, but larger trials are lacking.
Major:
CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir) can raise nifedipine plasma levels → increased risk of hypotension.
Potent CYP3A4 inducers (e.g., carbamazepine, rifampicin) may lower concentrations → reduced efficacy.
Moderate:
Other antihypertensives (ACE inhibitors, beta-blockers, diuretics) - additive blood-pressure lowering effect; monitor BP.
Simvastatin - concurrent use may increase simvastatin levels; consider alternative lipid-lowering therapy.
Patients should provide a full medication list, including over-the-counter products and herbal supplements, before starting Procardia.
Dosing may be adjusted in patients with hepatic or renal impairment, or in the elderly, based on clinical response and tolerability.
This article provides educational information about Procardia and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
